Correspondence 0001493152-24-005026 from Telomir Pharmaceuticals, Inc. (TELO) (CIK 0001971532) (TELO)
Telomir Pharmaceuticals, Inc. (TELO) (CIK 0001971532)
Date: Feb. 6, 2024 · CIK: 0001971532 · Accession: 0001493152-24-005026
AI Filing Summary & Sentiment
File numbers found in text: 333-275534
Letter
Kingswood Investments,
division of Kingswood Capital Partners, LLC
Battery Place, Suite 625
New York, New York 10004
February 6, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
Attention: Messrs. Jimmy McNamara and Jason Drory
Re: Telomir Pharmaceuticals, Inc.
Registration Statement on Form S-1
File No. 333-275534
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Requested Date: February 8, 2024
Requested Time: 4:30 pm, Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, as representative of the underwriters of the proposed public offering of securities of Telomir Pharmaceuticals, Inc. (the “Company”), hereby join the Company’s request that the effective date of the above-referenced registration statement on Form S-1, as amended, be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on February 8, 2024, or as soon thereafter as possible.
Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Kingswood
Investments,
Show Raw Text
CORRESP
1
filename1.htm
Kingswood
Investments,
division
of Kingswood Capital Partners, LLC
17
Battery Place, Suite 625
New
York, New York 10004
February 6, 2024
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
DC 20549
Attention:
Messrs. Jimmy McNamara and Jason Drory
Re:
Telomir Pharmaceuticals, Inc.
Registration
Statement on Form S-1
File
No. 333-275534
REQUEST
FOR ACCELERATION OF EFFECTIVENESS
Requested
Date: February 8, 2024
Requested
Time: 4:30 pm, Eastern Time
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, as representative of the underwriters
of the proposed public offering of securities of Telomir Pharmaceuticals, Inc. (the “Company”), hereby join the Company’s
request that the effective date of the above-referenced registration statement on Form S-1, as amended, be accelerated so that it will
be declared effective at 4:30 p.m., Eastern Time, on February 8, 2024, or as soon thereafter as possible.
Pursuant
to Rule 460 under the Securities Act, please be advised that we will distribute as many copies of the proposed form of preliminary prospectus
as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The
undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange
Act of 1934, as amended.
Very truly yours,
Kingswood
Investments,
division
of Kingswood Capital Partners, LLC
By:
/s/
Tyler Bashaw
Name:
Tyler Bashaw
Title:
Supervisory Principal